PRMT5 INHIBITORS

The present invention provides a compound selected from: and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods...

Full description

Saved in:
Bibliographic Details
Main Authors MACHACEK Michelle, WITTER David J, SLOMAN David L, GIBEAU Craig R, KAWAMURA Shuhei, ALTMAN Michael D
Format Patent
LanguageEnglish
Spanish
Published 23.09.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present invention provides a compound selected from: and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations. La presente invención proporciona un compuesto seleccionado de: (ver Fórmulas) y las sales, ésteres y profármacos farmacéuticamente aceptables de los mismos, que son inhibidores de PRMT5. También se proporcionan métodos para hacer compuestos descritos en la presente, composiciones farmacéuticas que comprenden los compuestos descritos en la presente y métodos para usar estos compuestos para tratar el cáncer, células falciformes y persistencia hereditaria de mutaciones de la hemoglobina fetal (HPFH).
AbstractList The present invention provides a compound selected from: and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations. La presente invención proporciona un compuesto seleccionado de: (ver Fórmulas) y las sales, ésteres y profármacos farmacéuticamente aceptables de los mismos, que son inhibidores de PRMT5. También se proporcionan métodos para hacer compuestos descritos en la presente, composiciones farmacéuticas que comprenden los compuestos descritos en la presente y métodos para usar estos compuestos para tratar el cáncer, células falciformes y persistencia hereditaria de mutaciones de la hemoglobina fetal (HPFH).
Author WITTER David J
ALTMAN Michael D
MACHACEK Michelle
SLOMAN David L
KAWAMURA Shuhei
GIBEAU Craig R
Author_xml – fullname: MACHACEK Michelle
– fullname: WITTER David J
– fullname: SLOMAN David L
– fullname: GIBEAU Craig R
– fullname: KAWAMURA Shuhei
– fullname: ALTMAN Michael D
BookMark eNrjYmDJy89L5WQQCAjyDTFV8PTz8HTyDPEPCuZhYE1LzClO5YXS3AxKbq4hzh66qQX58anFBYnJqXmpJfG-EUYGRkYGBuamxiaOxkQpAgAE3h_E
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate INHIBIDORES DE PRMT5.
ExternalDocumentID MX2022007534A
GroupedDBID EVB
ID FETCH-epo_espacenet_MX2022007534A3
IEDL.DBID EVB
IngestDate Fri Oct 04 04:57:00 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
Spanish
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_MX2022007534A3
Notes Application Number: MX2022007534
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220923&DB=EPODOC&CC=MX&NR=2022007534A
ParticipantIDs epo_espacenet_MX2022007534A
PublicationCentury 2000
PublicationDate 20220923
PublicationDateYYYYMMDD 2022-09-23
PublicationDate_xml – month: 09
  year: 2022
  text: 20220923
  day: 23
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies MERCK SHARP & DOHME LLC
RelatedCompanies_xml – name: MERCK SHARP & DOHME LLC
Score 3.2687016
Snippet The present invention provides a compound selected from: and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors....
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title PRMT5 INHIBITORS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220923&DB=EPODOC&locale=&CC=MX&NR=2022007534A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQAR1KBpr90TVMNTfTNUlONNVNTDJL1jW1SDEySkqyTDJNAq_y9TPzCDXxijCNYGLIhu2FAZ8TWg4-HBGYo5KB-b0EXF4XIAaxXMBrK4v1kzKBQvn2biG2LmrQ3rGRkQGwwaLm4mTrGuDv4u-s5uxs6xuh5hcEkQNWj8YmjswMrMB2tDkoO7iGOYG2pRQg1yluggxsAUDj8kqEGJhSi4UZOJ1hV68JM3D4Qme8gUxo5isWYRAICPINMVXw9PPwdPIM8Q8KFmVQcnMNcfbQBRodD_dIvG8EkjOMxRhYgD38VAkGBQOLZFPzxGQD42RghWpulmyZYphikWKQmGiSZG6ZZGYoySCNxyApvLLSDFwgHmiJg5GxDANLSVFpqiywHi1JkgP7HwAyY3Mb
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1JS8QwFH6Mozie1NFBHZdBpLdit3Q5FHG60Op0oVbprTRpDyLoYCv-fZPY0TnNLeTBIwl8-d7LWwJww5qSseiPKDeGLmqkQmKFdSIis1YUjC2MMM_yjfXgWXsoUDGAt1UtDO8T-s2bI1JEEYr3jt_Xy_9HLJfnVra3-JVOfdz5ue0KvXesKBI1WAR3bntp4iaO4Dh2VAhx9iuj9Khq91uwTW1sg8HBe5mzspTlOqf4B7CTUnXv3SEMmnYMI2f19doYdqM-4k2HPfjaI9hPsyhHszAOwnmYJ9nTMVz7Xu4EIlVd_m2kjIq1ZagTGFIPvzmBmWQSZFREUgklVEMnVi3XZi1VlYYNC-vyKUw3KDrbKL2CUZBHi3IRxo9T2GMSlu6gqOcw7D6_mgvKqR2-5GfxA8JQdg4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PRMT5+INHIBITORS&rft.inventor=MACHACEK+Michelle&rft.inventor=WITTER+David+J&rft.inventor=SLOMAN+David+L&rft.inventor=GIBEAU+Craig+R&rft.inventor=KAWAMURA+Shuhei&rft.inventor=ALTMAN+Michael+D&rft.date=2022-09-23&rft.externalDBID=A&rft.externalDocID=MX2022007534A